The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma
Open accessAbstract
Nonfunctioning pancreatic neuroendocrine tumors (NET) are defined by their histopathological differentiation. Neuroendocrine cells are characterized by the expression of marker molecules like neuron-specific enolase (NSE), an unspecific cytosolic marker or vesicle proteins like chromogranin A or synaptophysin, indicating large and dense hormone-storing core vesicles and neuropeptides- or small neurotransmitter-storing synaptic vesicles, respectively [1,2,3,4]. These proteins define the neuroendocrine origin of the tumor cells. The term ‘nonfunctioning’ refers to the absence of clinical symptoms of hormonal hypersecretion. However, nonfunctioning tumors may well show immunohistochemical positivity for hormones, neuropeptides or neurotransmitters. The WHO classifies nonfunctioning pancreatic NETs according to the uniform classification scheme for endocrine tumors, independent of the site of the primary: (1) well-differentiated endocrine tumor, with benign or uncertain behavior at the time of diagnosis; (2) well-differentiated endocrine carcinoma, with low-grade malignant behavior, and (3) poorly differentiated endocrine carcinoma, with high-grade malignant behavior [5] (table 1). Most (60–100%, according to the series) are classified as well-differentiated endocrine carcinomas [6, 7].Due to new and more sensitive imaging techniques, the number of neuroendocrine pancreatic incidentalomas has increased. The autoptic incidence is 1.6–10% per year [8], while the clinical incidence is 3.5–4/million/year [9]. Pancreatic endocrine tumors represent about 2–10% of all pancreatic tumors [9, 10]. In earlier series the percentage of nonfunctioning tumors out of all pancreatic endocrine tumors was estimated to be 18–66% [11,12,13,14,15,16,17]. In contrast, recent, large monocentric [7, 18, 19] or multicentric studies [20] classify 68–80% as nonfunctioning pancreatic neuroendocrine tumors. The peak incidence is during the fifth decade [6], with equal distribution among the sexes.Nonfunctioning pancreatic neuroendocrine tumors are defined by the absence of a hormone hypersecretion syndrome. The classification of the tumor as of neuroendocrine origin refers to the immunohistochemical positivity of chromogranin A and/or synaptophysin. Pathological grading is done according to the WHO classification of endocrine tumors; the majority are well-differentiated carcinomas. Pancreatic neuroendocrine tumors are rare.Due to the lack of symptoms related to hormonal hypersecretion, nonfunctioning pancreatic neuroendocrine tumors are diagnosed late in the course of the disease. The clinical signs and symptoms are due to the tumor mass, with local invasion and/or distant metastases. Abdominal pain is the major presenting symptom (35–78%), followed by weight loss (20–35%), anorexia and nausea (45%). The patient may present with intra-abdominal hemorrhage (4–20%), jaundice (17–50%) or a palpable mass (7–40%) [21,22,23,24,25]. Fifty-nine percent to 80% of the patients present with synchronous liver metastases at diagnosis [10, 25]. Given the mostly large primary (>5 cm), localizing the tumor at the head of the pancreas, followed by the body and tail, is straightforward [26].Most neuroendocrine pancreatic tumors are well-differentiated (WHO group 2) endocrine carcinomas (table 1) [27]. Overall 5-year survival is 30–63%, with a median survival from diagnosis of 72 months [12, 25, 28, 29]. Actuarial 5- and 10-year survival rates after diagnosis of liver metastases were 46 and 38%, respectively. [10]. However, aggressive treatment may increase 5-year survival to 63 or 82% [25, 30]. Rapid progression of liver metastases (more than 25% volume increase within 6–12 months) and the development of bone metastases confer a poor prognosis [10]. Histopathological staging (table 1), including tumor differentiation, tumor size, proliferation marker and angioinvasion, correlates with survival. All patients with low-risk tumors were alive after 47 months, 10% of those with intermediate-risk tumors had died after 94 months, while 35% of patients with low-grade malignant tumors died after a period of 42 months. Few patients with a high-grade malignant tumor were alive after 4 months [27].Nonfunctioning pancreatic neuroendocrine tumors present as large tumors, with signs and symptoms related to the tumor burden. At diagnosis, the prevalence of synchronous metastases is 80%. Prognosis depends on the presence or absence of liver/bone metastases and histopathological classification. Overall 5-year survival is 60%. MEN-1. Multiple endocrine neoplasia type 1 (MEN-1) is a hereditary tumor syndrome with autosomal inheritance and high penetrance. The main manifestations of the disease are primary hyperparathyroidism, pituitary adenomas and pancreatic neuroendocrine tumors. Nonfunctioning pancreatic neuroendocrine tumors occur besides functional tumors. MEN-1-related tumors occur at an earlier age and demonstrate a more benign course than do sporadic tumors. They may be
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Self-citationMoertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., & Klaassen, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260804 · Cited by 976
Sarmiento, J. M., Heywood, G., Rubin, J., Ilstrup, D. M., Nagorney, D. M., & Que, F. G. (2003) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(03)00230-8 · Cited by 773
Localization of Pancreatic Endocrine Tumors by Endoscopic Ultrasonography
Rösch, T., Lightdale, C. J., Botet, J. F., Boyce, G. A., Sivak, M. V., Yasuda, K., Heyder, N., Palazzo, L., Dancygier, H., Schusdziarra, V., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262601 · Cited by 713
Hepatic neuroendocrine metastases: does intervention alter outcomes?1
Chamberlain, R. S., Canes, D., Brown, K. T., Saltz, L., Jarnagin, W., Fong, Y., & Blumgart, L. H. (2000) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(00)00222-2 · Cited by 622
Kouvaraki, M. A., Ajani, J. A., Hoff, P., Wolff, R., Evans, D. B., Lozano, R., & Yao, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.024 · Cited by 607
Faiss, S., Pape, U.-F., Böhmig, M., Dörffel, Y., Mansmann, U., Golder, W., Riecken, E. O., & Wiedenmann, B. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.142 · Cited by 501
Self-citationSynaptophysin: a marker protein for neuroendocrine cells and neoplasms.
Wiedenmann, B., Franke, W. W., Kuhn, C., Moll, R., & Gould, V. E. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.10.3500 · Cited by 496
Hepatic resection for metastatic neuroendocrine carcinomas
Que, F. G., Nagorney, D. M., Batts, K. P., Linz, L. J., & Kvols, L. K. (1995) · The American Journal of Surgery · doi:10.1016/s0002-9610(99)80107-x · Cited by 462
Self-citationGupta, S., Johnson, M. M., Murthy, R., Ahrar, K., Wallace, M. J., Madoff, D. C., McRae, S. E., Hicks, M. E., Rao, S., Vauthey, J., et al. (2005) · Cancer · doi:10.1002/cncr.21389 · Cited by 433
Kwekkeboom, D. J., Bakker, W. H., Kam, B. L., Teunissen, J. J. M., Kooij, P. P. M., de Herder, W. W., Feelders, R. A., van Eijck, C. H. J., de Jong, M., Srinivasan, A., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1050-8 · Cited by 424
Self-citationCytoreductive hepatic surgery for neuroendocrine tumors.
Gp, M., Nagorney, D. M., Lk, K., Cg, M., & Cs, G. (1990) · PubMed · Cited by 381
Isolated Liver Metastases from Neuroendocrine Tumors: Does Resection Prolong Survival?
Chen, H., Hardacre, J. M., Uzar, A., Cameron, J. L., & Choti, M. A. (1998) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(98)00099-4 · Cited by 371
Kwekkeboom, D. J., Mueller‐Brand, J., Paganelli, G., Anthony, L. B., Pauwels, S. A., Kvols, L. K., O’Dorisio, T. M., Valkema, R., Bodei, L., Chinol, M., et al. (2005) · PubMed · Cited by 367
Self-citationNeuroendocrine Hepatic Metastases: Does Aggressive Management Improve Survival?
Touzios, J. G., Kiely, J. M., Pitt, S. C., Rilling, W. S., Quebbeman, E. J., Wilson, S. D., & Pitt, H. A. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000161981.58631.ab · Cited by 362
Sun, W., Lipsitz, S., Catalano, P., Mailliard, J. A., & Haller, D. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.616 · Cited by 357
Arnold, R., Trautmann, M. E., Creutzfeldt, W., Benning, R., Benning, M., Neuhaus, C., Jürgensen, R., Stein, K., Schäfer, H., Bruns, C., et al. (1996) · Gut · doi:10.1136/gut.38.3.430 · Cited by 342
Specific Endocrine Tissue Marker Defined by a Monoclonal Antibody
Lloyd, R. V., & Wilson, B. S. (1983) · Science · doi:10.1126/science.6635661 · Cited by 337
Di Bartolomeo, M., Bajetta, E., Buzzoni, R., Mariani, L., Carnaghi, C., Somma, L., Zilembo, N., Di Leo, A., & ITMO Association (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960115)77:2<402::aid-cncr25>3.0.co;2-4 · Cited by 296
Islet Cell Tumor of the Pancreas: Biphasic CT versus MR Imaging in Tumor Detection
Ichikawa, T., Peterson, M. S., Federle, M. P., Baron, R. L., Haradome, H., Kawamori, Y., Nawano, S., & Araki, T. (2000) · Radiology · doi:10.1148/radiology.216.1.r00jl26163 · Cited by 275
Results of Liver Transplantation in the Treatment of Metastatic Neuroendocrine Tumors
Treut, Y. P. L., Delpéro, J., Dousset, B. E., Cherqui, D., Segol, P., Mantion, G., Hannoun, L., Benhamou, G., Launois, B., Boillot, O., et al. (1997) · Annals of Surgery · doi:10.1097/00000658-199704000-00003 · Cited by 272
LIVER TRANSPLANTATION FOR METASTATIC NEUROENDOCRINE CARCINOMA: An Analysis of 103 Patients
Lehnert, T. (1998) · Transplantation · doi:10.1097/00007890-199811270-00007 · Cited by 268
Treatment with cisplatin and etoposide in patients with neuroendocrine tumors
Fj�llskog, M.-L. H., Granberg, D. P. K., Welin, S. L. V., Eriksson, C., �berg, K. E., Janson, E. T., & Eriksson, B. K. (2001) · Cancer · doi:10.1002/1097-0142(20010901)92:5<1101::aid-cncr1426>3.0.co;2-v · Cited by 262
Self-citationAndrews, J. C., Walker, S., Ackermann, R. J., Cotton, L., Ensminger, W. D., & Shapiro, B. (1994) · PubMed · Cited by 261
Saltz, L., Trochanowski, B., Buckley, M., Heffernan, B., Niedzwiecki, D., Tao, Y., & Kelsen, D. (1993) · Cancer · doi:10.1002/1097-0142(19930701)72:1<244::aid-cncr2820720143>3.0.co;2-q · Cited by 260
Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases
Siperstein, A. E., Rogers, S. J., Hansen, P. D., & Gitomirsky, A. (1997) · Surgery · doi:10.1016/s0039-6060(97)90221-x · Cited by 260
Clinical pathology of endocrine tumors of the pancreas: Analysis of autopsy cases
Kimura, W., Kuroda, A., & Morioka, Y. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01297144 · Cited by 259
Couvelard, A., O'Toole, D., Turley, H., Leek, R., Sauvanet, A., Degott, C., Ruszniewski, P., Belghiti, J., Harris, A. L., Gatter, K., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602245 · Cited by 257
Arnold, R., Rinke, A., Klose, K.-J., Müller, H.-H., Wied, M., Zamzow, K., Schmidt, C., Schade-Brittinger, C., Barth, P., Moll, R., et al. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00481-7 · Cited by 254
Lethality of Multiple Endocrine Neoplasia Type I
Doherty, G. M., Olson, J. A., Frisella, M. M., Lairmore, T. C., Wells, S. A., & Norton, J. A. (1998) · World Journal of Surgery · doi:10.1007/s002689900438 · Cited by 252
Triponez, F., Dosseh, D., Goudet, P., Cougard, P., Bauters, C., Murat, A., Cadiot, G., Niccoli-Sire, P., Chayvialle, J.-A., Calender, A., et al. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000197715.96762.68 · Cited by 251
Islet cell carcinomas of the pancreas: a twenty-year experience.
Thompson, G. B., van Heerden, J. A., Grant, C. S., Carney, J. A., & Ilstrup, D. M. (1988) · PubMed · Cited by 249
Klöppel, G., & Heitz, P. U. (1988) · Pathology - Research and Practice · doi:10.1016/s0344-0338(88)80043-8 · Cited by 248
Prognostic criteria in nonfunctioning pancreatic endocrine tumours
La Rosa, S., Capella, C., Sessa, F., Riva, C., Leone, B. E., Klersy, C., Rindi, G., & Solcia, E. (1996) · Virchows Archiv · doi:10.1007/bf00198436 · Cited by 246
Fuhrman, G. M., Charnsangavej, C., Abbruzzese, J. L., Cleary, K. R., Martin, R. G., Fenoglio, C. J., & Evans, D. B. (1994) · The American Journal of Surgery · doi:10.1016/0002-9610(94)90060-4 · Cited by 244
Lebtahi, R., Cadiot, G., Sarda‐Mantel, L., Daou, D., Faraggi, M., Petegnief, Y., Mignon, M., & Guludec, D. L. (1997) · PubMed · Cited by 240
Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients
Phan, G. Q., Yeo, C. J., Hruban, R. H., Lillemoe, K. D., Pitt, H. A., & Cameron, J. L. (1998) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(98)80039-5 · Cited by 239
Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings.
Hough, D. M., Stephens, D. H., Johnson, C. D., & Binkovitz, L. A. (1994) · American Journal of Roentgenology · doi:10.2214/ajr.162.5.8165988 · Cited by 237
Laparoscopic Radiofrequency Ablation of Neuroendocrine Liver Metastases
Berber, E., Flesher, N., & Siperstein, A. E. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6629-5 · Cited by 236
Hepatic surgery for metastases from neuroendocrine tumors
Sarmiento, J. M., & Que, F. G. (2003) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(02)00076-5 · Cited by 227
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours
Aparicio, T., Ducreux, M., Baudin, E., Sabourin, J.-C., De Baere, T., Mitry, E., Schlumberger, M., & Rougier, P. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00073-9 · Cited by 226
Anlauf, M., Schlenger, R., Perren, A., Bauersfeld, J., Koch, C. A., Dralle, H., Raffel, A., Knoefel, W. T., Weihe, E., Ruszniewski, P., et al. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000194044.01104.25 · Cited by 223
Local Recurrence After Laparoscopic Radiofrequency Thermal Ablation of Hepatic Tumors
Siperstein, A., Garland, A., Engle, K., Rogers, S., Berber, E., Foroutani, A., String, A., Ryan, T., & Ituarte, P. (2000) · Annals of Surgical Oncology · doi:10.1007/s10434-000-0106-x · Cited by 223
PGP 9.5, a new marker for human neuroendocrine tumours
RODE, J., DHILLON, A. P., DORAN, J. F., JACKSON, P., & THOMPSON, R. J. (1985) · Histopathology · doi:10.1111/j.1365-2559.1985.tb02431.x · Cited by 221
Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors
Norton, J. A. (2003) · Archives of Surgery · doi:10.1001/archsurg.138.8.859 · Cited by 221
Imaging and localization of islet-cell tumours of the pancreas on CT and MRI.
Noone, T. C., Hosey, J., Firat, Z., & Semelka, R. C. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.11.013 · Cited by 217
Pancreatic lesions in the von Hippel-Lindau syndrome
Neumann, H. P. H., Dinkel, E., Brambs, H., Wimmer, B., Friedburg, H., Volk, B., Sigmund, G., Riegler, P., Haag, K., Schollmeyer, P., et al. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90026-h · Cited by 214
Triponez, F., Goudet, P., Dosseh, D., Cougard, P., Bauters, C., Murat, A., Cadiot, G., Niccoli‐Sire, P., Calender, A., & Proye, C. A. G. (2006) · World Journal of Surgery · doi:10.1007/s00268-005-0354-9 · Cited by 209
Neuroendocrine tumors of the pancreas: Spectrum of appearances on MRI
Semelka, R. C., Custodio, C. M., Balci, N. C., & Woosley, J. T. (2000) · Journal of Magnetic Resonance Imaging · Cited by 197
The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
Ducreux, M. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02003-7 · Cited by 196
Are Patients with Multiple Endocrine Neoplasia Type I Prone to Premature Death?
Dean, P. G., van Heerden, J. A., Farley, D. R., Thompson, G. B., Grant, C. S., Harmsen, W. S., & Ilstrup, D. M. (2000) · World Journal of Surgery · doi:10.1007/s002680010237 · Cited by 194
Rosenau, J., Bahr, M. J., von Wasielewski, R., Mengel, M., Schmidt, H. H. J., Nashan, B., Lang, H., Klempnauer, J., Manns, M. P., & Boeker, K. H. W. (2002) · Transplantation · doi:10.1097/00007890-200202150-00012 · Cited by 188
Ramanathan, R. K., Cnaan, A., Hahn, R. G., Carbone, P. P., & Haller, D. G. (2001) · Annals of Oncology · doi:10.1023/a:1011632713360 · Cited by 181
Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours
Nehar, D., Lombard‐Bohas, C., Olivieri, S., Claustrat, B., Chayvialle, J., Penes, M., Sassolas, G., & Borson‐Chazot, F. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02030.x · Cited by 177
Middle Segment Pancreatectomy: A Novel Technique for Conserving Pancreatic Tissue
Warshaw, A. L., Rattner, D. W., Fernández-del Castillo, C., & Z'graggen, K. (1998) · Archives of Surgery · doi:10.1001/archsurg.133.3.327 · Cited by 177
Transcatheter chemoembolization of progressive carcinoid liver metastasis.
Therasse, E., Breittmayer, F., Roche, A., De Baere, T., Indushekar, S., Ducreux, M., Lasser, P., Elias, D., & Rougier, P. (1993) · Radiology · doi:10.1148/radiology.189.2.7692465 · Cited by 172
Eriksson, B., Skogseid, B., Lundqvist, G., Wide, L., Wilander, E., & Öberg, K. (1990) · Cancer · doi:10.1002/1097-0142(19900501)65:9<1883::aid-cncr2820650902>3.0.co;2-3 · Cited by 168
Self-citationHepatic Arterial Chemoembolization for Metastatic Neuroendocrine Tumors
Clouse, M. E., Perry, L., Stuart, K., & Stokes, K. R. (1994) · Digestion · doi:10.1159/000201208 · Cited by 167
Broughan, T. A., Jd, L., Jm, S., & Hermann, R. E. (1986) · PubMed · Cited by 167
Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors
Marion-Audibert, A.-M., Barel, C., Gouysse, G., Dumortier, J., Pilleul, F., Pourreyron, C., Hervieu, V., Poncet, G., Lombard‐Bohas, C., Chayvialle, J., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01198-3 · Cited by 164
Self-citationRadiofrequency Tissue Ablation Using Cooled Tip for Liver Metastases of Endocrine Tumors
Hellman, P., Ladjevardi, S., Skogseid, B., Åkerström, G., & Elvin, A. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6663-3 · Cited by 159
Van Hoe, L., Gryspeerdt, S., Marchal, G., Baert, A. L., & Mertens, L. (1995) · American Journal of Roentgenology · doi:10.2214/ajr.165.6.7484581 · Cited by 159
MRI of pancreatic neuroendocrine tumours
Owen, N. J., Sohaib, S. A. A., Peppercorn, P. D., Monson, J. P., Grossman, A. B., Besser, G. M., & Reznek, R. H. (2001) · The British Journal of Radiology · doi:10.1259/bjr.74.886.740968 · Cited by 158
Kress, O., Wagner, H., Wied, M., Klose, K.-J., Arnold, R., & Alfke, H. (2003) · Digestion · doi:10.1159/000074522 · Cited by 150
Pancreatic Islet Cell Carcinoma: I. Clinical Features of 52 Patients
Broder, L. E., & Carter, S. K. (1973) · Annals of Internal Medicine · doi:10.7326/0003-4819-79-1-101 · Cited by 149
Wiedenmann, B., Jensen, R. T., Mignon, M., Modlin, C. I., Skogseid, B. M., Doherty, G. M., & Öberg, K. (1998) · World Journal of Surgery · doi:10.1007/s002689900387 · Cited by 148
Self-citationRadiofrequency ablation of neuroendocrine liver metastases—the Middlesex experience
Gillams, A. R., Cassoni, A. M., Conway, G. S., & Lees, W. R. (2005) · Abdominal Imaging · doi:10.1007/s00261-004-0258-4 · Cited by 145
State-of-the-art imaging of pancreatic neoplasms
Kalra, M. K., Maher, M. M., Müeller, P. R., & Saini, S. (2003) · British Journal of Radiology · doi:10.1259/bjr/16642775 · Cited by 142
Panzuto, F., Fonzo, M. D., Iannicelli, E., Sciuto, R., MAINI, C. L., Capurso, G., Milione, M., Cattaruzza, M. S., Falconi, M., David, V., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj113 · Cited by 138
Self-citationPape, U., Böhmig, M., Berndt, U., Tiling, N., Wiedenmann, B., & Plöckinger, U. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1294.025 · Cited by 137
Self-citationHepatic arterial chemoembolization for metastatic neuroendocrine tumors.
Perry, L. J., Stuart, K. E., Stokes, K. R., & Clouse, M. E. (1994) · PubMed · Cited by 135
An Update of the Medical Treatment of Malignant Endocrine Pancreatic Tumors
Eriksson, B. K., & Öberg, K. (1993) · Acta Oncologica · doi:10.3109/02841869309083913 · Cited by 135
Self-citationBuetow, P. C., Miller, D. L., Parrino, T. V., & Buck, J. (1997) · Radiographics · doi:10.1148/radiographics.17.2.9084084 · Cited by 132
Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR
Tomassetti, Migliori, Corinaldesi, & Gullo (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00738.x · Cited by 125
Natural History of Neuroendocrine Enteropancreatic Tumors
Mignon, M. (2000) · Digestion · doi:10.1159/000051856 · Cited by 124
ERIKSSON, B., Arnberg, H., Lindgren, P. G., LÖRELIUS, L. ‐., MAGNUSSON, A., Lundqvist, G., Skogseid, B. M., WIDE, L. E., Wilander, E., & Öberg, K. (1990) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1990.tb00202.x · Cited by 122
Self-citationNonfunctioning islet cell carcinoma of the pancreas.
Evans, D. B., Skibber, J. M., Lee, J. E., Cleary, K. R., Ajani, J. A., Gagel, R. F., Sellin, R. V., Fenoglio, C. J., Merrell, R. C., & Hickey, R. C. (1993) · PubMed · Cited by 117
Faiss, S., Räth, U., Mansmann, U., Caird, D. M., Clemens, N., Riecken, E. O., & Wiedenmann, B. (1999) · Digestion · doi:10.1159/000007693 · Cited by 116
Diagnosis, Staging, and Surveillance of Pancreatic Cancer
Tamm, E. P., Silverman, P. M., Charnsangavej, C., & Evans, D. B. (2003) · American Journal of Roentgenology · doi:10.2214/ajr.180.5.1801311 · Cited by 116
Diaco, D. S., Hajarizadeh, H., Mueller, C. R., Fletcher, W. S., Pommier, R. F., & Woltering, E. A. (1995) · The American Journal of Surgery · doi:10.1016/s0002-9610(99)80210-4 · Cited by 115
Surgery for Asymptomatic Pancreatic Lesion in Multiple Endocrine Neoplasia Type I
Skogseid, B. M., Öberg, K., Eriksson, B., Juhlin, C. C., Granberg, D. O., Åkerström, G., & Rastad, J. (1996) · World Journal of Surgery · doi:10.1007/s002689900133 · Cited by 113
Self-citationUğur, Ö., Kothari, P. J., Finn, R. D., ZANZONICO, P. B., Ruan, S., Guenther, I., Maëcke, H. R., & Larson, S. M. (2002) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(01)00290-6 · Cited by 113
Endoscopic Ultrasonography of Neuroendocrine Tumours
Zimmer, T., Scherübl, H., Faiss, S., Stölzel, U., Riecken, E. O., & Wiedenmann, B. (2000) · Digestion · doi:10.1159/000051855 · Cited by 113
Grama, D., Eriksson, B. K., Mårtensson, H., Cedermark, B., Åhrén, B., Kristoffersson, A., Rastad, J., Öberg, K., & Åkerström, G. (1992) · World Journal of Surgery · doi:10.1007/bf02067341 · Cited by 111
Self-citationMalignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood
Verhoef, S., van Diemen-Steenvoorde, R., Akkersdijk, W. L., Bax, N. M. A., Ariyürek, Y., Hermans, C. J., van Nieuwenhuizen, O., Nikkels, P. G. J., Lindhout, D., Halley, D. J. J., et al. (1999) · European Journal of Pediatrics · doi:10.1007/s004310051073 · Cited by 109
Lowney, J. K., Frisella, M. M., Lairmore, T. C., & Doherty, G. M. (1998) · Surgery · doi:10.1067/msy.1998.92561 · Cited by 104
Grama, D., Skogseid, B. M., Wilander, E., Eriksson, B. K., Mårtensson, H., Cedermark, B., Åhrén, B., Kristofferson, A. O., Öberg, K., Rastad, J., et al. (1992) · World Journal of Surgery · doi:10.1007/bf02067335 · Cited by 102
Self-citationOBRIEN, J. (1976) · The Lancet · doi:10.1016/s0140-6736(76)92075-4 · Cited by 94
Indications and Results of Liver Transplantation in Patients with Neuroendocrine Tumors
Olausson, M., Friman, S., Cahlin, C., Nilsson, O., Jansson, S. K. G., Wängberg, B., & Ahlman, H. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6631-y · Cited by 93
Froidevaux, S., Eberlé, A. N., Christe, M., Sumanovski, L. T., Heppeler, A., Schmitt, J. S., Eisenwiener, K., Beglinger, C., & Mäcke, H. R. (2002) · International Journal of Cancer · doi:10.1002/ijc.10295 · Cited by 92
Standardisation of imaging in neuroendocrine tumours: results of a European delphi process
Ricke, J., Klose, K.-J., Mignon, M., Öberg, K., & Wiedenmann, B. (2001) · European Journal of Radiology · doi:10.1016/s0720-048x(00)00187-x · Cited by 92
Self-citationÅkerström, G., Hessman, O., & Skogseid, B. M. (2002) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-001-0274-6 · Cited by 87
Surgical Strategy for Large or Malignant Endocrine Pancreatic Tumors
Hellman, P., Andersson, M., Rastad, J., Juhlin, C., Karacagil, S., Eriksson, B. K., Skogseid, B. M., & Åkerström, G. (2000) · World Journal of Surgery · doi:10.1007/s002680010224 · Cited by 86
Malignant Pancreatic Endocrine Tumor in a Child With Tuberous Sclerosis
Francalanci, P., Diomedi‐Camassei, F., Purificato, C., Santorelli, F. M., Giannotti, A., Dominici, C., Inserra, A., & Boldrini, R. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200310000-00012 · Cited by 81
Surgical Treatment of Benign and Borderline Neoplasms of the Pancreatic Body
Balzano, G., Zerbi, A., Veronesi, P., et al. (2003) · Digestive Surgery · doi:10.1159/000073646 · Cited by 74
Interventional Treatment of Gastrointestinal Neuroendocrine Tumours
Ahlman, H. K., Wängberg, B., Jansson, S., Friman, S., Olausson, M., Tylén, U., & Nilsson, O. (2000) · Digestion · doi:10.1159/000051857 · Cited by 67
Stivanello, M., Berruti, A., TORTA, M., Termine, A., Tampellini, M., Gorzegno, G., Angeli, A., & Dogliotti, L. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_2.s73 · Cited by 66
Liver Transplantation for Treatment of Metastatic Neuroendocrine Tumors
Ahlman, H., Friman, S., Cahlin, C., Nilsson, O., Jansson, S. K. G., Wängberg, B., & Olausson, M. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1294.029 · Cited by 65
Gastroenteropancreatic Endocrine Tumours: Effect of Sandostatin® on Tumour Growth
Arnold, R., Benning, R., Neuhaus, C., et al. (2009) · Digestion · doi:10.1159/000201081 · Cited by 65
Dhabuwala, A., Lamerton, P., & Stubbs, R. S. (2005) · BMC Nuclear Medicine · doi:10.1186/1471-2385-5-7 · Cited by 62
Nino‐Murcia, M., Tamm, E. P., Charnsangavej, C., & Jeffrey, R. B. (2003) · Abdominal Imaging · doi:10.1007/s00261-002-0056-9 · Cited by 61
Effective treatment of neuroendocrine tumors With temozolomide and capecitabine
Fine, R. L., Fogelman, D. R., & Schreibman, S. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4216 · Cited by 60
Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors.
Bombardieri, E., Seregni, E. C., Villano, C., Chiti, A., & Bajetta, E. (2004) · PubMed · Cited by 56
Gastroenteropancreatic endocrine tumors: Effect of Sandostatin® on tumor growth
Arnold, R., Benning, R., Neuhaus, C., Rolwage, M., & TRAUTMANN, M. E. (1992) · Metabolism · doi:10.1016/0026-0495(92)90044-b · Cited by 36
Corleto, V. D., Panzuto, F., Falconi, M., Cannizzaro, R., Angeletti, S., Moretti, A., Fave, G. D., & Farinati, F. (2001) · Digestive and Liver Disease · doi:10.1016/s1590-8658(01)80710-6 · Cited by 33
Self-citationImaging of Neuroendocrine Tumors of the Pancreas
Fidler, J. L., & Johnson, C. D. (2001) · International Journal of Gastrointestinal Cancer · doi:10.1385/ijgc:30:1-2:073 · Cited by 31
Effects of the Tyrosine Kinase Inhibitor Imatinib on Neuroendocrine Tumor Cell Growth
Lankat–Buttgereit, B., Hörsch, D., Barth, P. J., Arnold, R., Blöcker, S., & Göke, R. (2005) · Digestion · doi:10.1159/000084647 · Cited by 24
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Cited by
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors
Metz, D. C., & Jensen, R. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.047 · Cited by 816
Jensen, R. T., Cadiot, G., Brandi, M. L., de Herder, W. W., Kaltsas, G., Komminoth, P., Scoazec, J.-Y., Salazar, R., Sauvanet, A., & Kianmanesh, R. (2012) · Neuroendocrinology · doi:10.1159/000335591 · Cited by 622
Self-citationNANETS Treatment Guidelines: Well-Differentiated Neuroendocrine Tumors of the Stomach and Pancreas
Kulke, M. H., Anthony, L. B., Bushnell, D. L., de Herder, W. W., Goldsmith, S. J., Klimstra, D. S., Marx, S. J., Pasieka, J. L., Pommier, R. F., Yao, J. C., et al. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb168 · Cited by 574
Metadata
- Authors
- Falconi, M., Plöckinger, U., Kwekkeboom, D. J., Manfredi, R., Körner, M., Kvols, L., Pape, U. F., Ricke, J., Goretzki, P. E., Wildi, S., Steinmüller, T., Öberg, K., & Scoazec, J.-Y.
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2006
- Volume
- 84
- Issue
- 3
- Pages
- 196-211
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2090969217
- Cited by
- 257
- References
- 108
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.